Key result
Intermediate and poor CYP2C19 metabolizers had a higher risk of ischemic stroke recurrence compared with extensive metabolizers.
Why the study?
CYP2C19 genetic variation may be involved in ASCVD, but its effect on serum lipid metabolism remains unclear.
Are CYP2C19 gene polymorphisms associated with altered lipid metabolism and risk of recurrence in Chinese patients with ischemic stroke?
Cohort (n=330)
Are CYP2C19 gene polymorphisms associated with altered lipid metabolism and risk of recurrence in Chinese patients with ischemic stroke?
CYP2C19 gene polymorphisms are associated with altered lipid metabolism and a higher risk of disease recurrence in Chinese patients with ischemic stroke.
May link CYP2C19 variants to lipid levels in ischemic stroke; hypothesis-generating and requires prospective validation before clinical use.
Objective The CYP2C19 genetic variation may be involved in the development of atherosclerotic cardiovascular disease (ASCVD). Serum lipid levels are important risk factors for ASCVD, but the effect of the CYP2C19 gene on serum lipid metabolism remains unclear. This retrospective cohort study investigated the relationship between the CYP2C19 gene polymorphism and serum lipid levels in patients with ischemic stroke (IS). Methods IS patients (n = 230) and control subjects (n = 100) were enrolled. All patients were diagnosed with IS via clinical manifestations and brain magnetic resonance imaging. All patients were genotyped. Results Triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c), and apolipoprotein B (ApoB) levels were significantly higher and high-density lipoprotein-cholesterol (HDL-c) and apolipoprotein A 1 (ApoA 1 ) levels were significantly lower in the IS group compared with the control group. Lower ApoA 1 levels and higher ApoB levels were significant predictive factors for IS. Patients with higher ApoB levels had a higher risk of IS recurrence. Compared with extensive metabolizers, intermediate and poor CYP2C19 metabolizers had a higher risk of IS recurrence. Conclusions Our study indicates CYP2C19 gene polymorphisms are related to lipid metabolism in patients with IS. IS patients who are poor CYP2C19 metabolizers may have a higher risk of disease recurrence.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2020) conducted a cohort in Ischemic stroke (n=330). CYP2C19 gene polymorphism (intermediate and poor metabolizers) vs. Extensive metabolizers was evaluated on Ischemic stroke recurrence and serum lipid levels. Intermediate and poor CYP2C19 metabolizers had a higher risk of ischemic stroke recurrence compared with extensive metabolizers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: